TLPHNasdaqPharmaceutical PreparationsFiscal year ends December 31

TALPHERA, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$1.08+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $81.57M
P/E (TTM): –
Dividend yield: –

TALPHERA, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Revenue	0.03	0	0.65	0	2.82	5.42	2.29	2.15	8.00	17	19	5.22	30	2.39	1.07	–	–	–	–	–
Cost of Revenue	–	–	–	2.59	3.75	6.03	6.81	3.98	11	12	1.77	–	–	–	–	–	–	–	–	–
Gross Profit	–	–	–	-2.59	-0.94	-0.62	-4.52	-1.83	-2.66	5.04	17	–	–	–	–	–	–	–	–	–
Research & Development	6.03	6.72	5.55	3.34	4.10	4.02	4.66	13	19	21	22	25	26	25	14	8.19	16	–	–	–
Selling, General & Admin	7.48	8.53	12	17	31	36	45	21	17	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	21	17	16	14	18	9.88	7.20	6.80	3.99	3.53	–	–	–
Advertising Expenses	–	–	–	–	–	0.50	1.10	0.50	0	–	–	–	–	–	–	–	–	–	–	–
Operating Expenses	–	–	–	–	–	–	–	38	47	49	39	43	36	32	20	12	19	–	–	–
Total Costs & Expenses	14	15	18	25	39	46	56	38	47	–	–	–	–	–	–	–	–	–	–	–
Operating Income	-13	-15	-17	-25	-36	-41	-54	-36	-39	-32	-20	-38	-6.67	–	–	–	–	–	–	–
Interest Expense	–	0	0.13	1.12	2.29	3.31	2.54	2.22	3.32	2.77	2.98	2.64	1.52	2.28	2.31	1.40	1.24	–	–	–
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.05	0.00	0.03	–	–	–
Other Non-Operating Income	-0.88	2.25	6.60	84	0.87	0.59	0.97	-11	-14	-11	-3.69	4.30	-17	-1.37	1.56	-0.76	0.12	–	–	–
Merger & Restructuring Charges	–	–	–	0.50	–	0.50	–	–	–	–	0.76	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	–	–	0	4.95	–	–	–	–	–	–	–	0	0	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.03	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.01	–	–	–	–
Pretax Income	–	–	-10	59	-35	-40	-53	-47	-52	-43	-24	-33	-23	-30	-19	-12	-19	–	–	–
Income Tax Expense	0	0	0	0.01	0.01	0.00	0.00	0.00	-0.70	-0.03	0.76	0	0	0	0	–	–	–	–	–
Income from Continuing Operations	-14	-13	-10	59	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income from Discontinued Operations	0.07	0	-8.11	-11	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-14	-13	-18	48	-35	-40	-53	-47	-52	-43	-24	-33	-23	-33	-20	-14	-20	-21	-9.63	-3.77
Net Income to Common	–	–	-18	42	-35	–	–	–	-52	-43	-27	-40	-23	-33	–	–	–	–	–	–
EPS (Basic)(per share)	-0.34	-0.50	-1.29	5.73	-5.86	-9.40	-13.40	-16.20	-22.00	-19.00	-11.00	-15.40	-11.80	-30.20	-23.20	-436.80	-698.60	–	–	–
EPS (Diluted)(per share)	–	–	-1.29	5.72	-5.86	-9.40	-13.40	-16.20	-22.00	-19.00	-12.00	-18.20	-11.80	-30.20	-23.20	-436.80	-698.60	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	42	26	14	7.39	5.99	4.26	3.96	2.92	2.34	2.27	2.22	2.17	1.99	1.11	0.87	0.03	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	42	26	14	7.41	5.99	4.26	3.96	2.92	2.34	2.27	2.22	2.22	1.99	1.11	0.87	0.03	–	–	–	–
EBITDA	–	-15	-17	-24	-34	-39	-53	-35	-37	-30	-18	-37	-6.07	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -1474700.0%
Net margin: -1507600.0%
Return on equity, FY2025: -114.2%

Financial strength

Current ratio: 4.29
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 17.7%

Valuation

P/E ratio: –
Price to sales: 81569.05
Price to book: 5.66
Dividend yield: –